Print this page

Life Sciences

Find venture funding. Protect your intellectual property. Engage corporate partners and access capital markets.

Life sciences companies require an extraordinary range of expertise in law, business and science. We’ve built our practice to anticipate these needs, and to provide effective, efficient counsel along the way.

With more than 100 experienced life sciences attorneys, Goodwin Procter has one of the leading practices in the United States. We have recently been named the 2015 U.S. News-Best Lawyers’ “Law Firm of the Year” in Biotechnology Law. Our clients include more than 400 private and public life sciences companies, from start-ups to Fortune 100 corporations. We understand the life cycle of growing companies, and have designed our practice to anticipate and address needs at every stage. Our firm represents 200 private equity, venture capital, and investment banking companies, and we leverage those relationships on behalf of our entrepreneurial clients. We’re known for structuring M & A and capital markets transactions, blending technical skills, specific industry expertise and practical judgment to ensure deals get done.

[[Read More Delimiter]]

Addressing client needs from a broad perspective is critically important. Lawyers in our life sciences practice provide expertise in corporate law, collaborations and licensing, regulatory matters, and intellectual property law. As part of our interdisciplinary approach, we collaborate with attorneys in our patent prosecution, products liability, employment, and FDA counseling practices to protect client interests and to advocate on their behalf. Our collective experience helps clients capitalize on opportunities while minimizing risks.

Our team includes professionals with 50+ advanced degrees, including 20 PhDs in disciplines ranging from organic chemistry, molecular and cell biology, and pharmacology, to biophysics and medicine, and is led by lawyers whose practice is exclusively focused on the life sciences industry. We understand the science that supports this industry.

We’re keenly aware of the issues facing life sciences companies, including the general business challenges and technology-specific capital needs, and the importance of key relationships with research institutions, scientists, and doctors. We also recognize the larger financial demands on research, development, and FDA approval, and are committed to providing pragmatic and efficient legal solutions at a reasonable cost.

Good Wins Update
December 6, 2011

BioPharm America 2014
September 22, 2014
Boston, MA

Michigan Growth Capital Symposium
June 17, 2014
Ypsilanti, MI

UCSF Course Series: Idea to IPO
February 10, 2014
San Francisco, CA

AFBO Boston - Year End Conference
December 11, 2013
Cambridge, MA

Nature SciCafe
October 24, 2013
Cambridge, MA

athenahealth's More Disruption Please Conference
October 2, 2013
Northpointe, MA

AdvaMed 2013
September 23, 2013

BioPharm America 2013
September 17, 2013
Boston, MA

Health 2.0 Matchpoint East Program
June 25, 2013
New York, NY

Milken Institute Global Conference 2013
April 28, 2013
Los Angeles, CA

AMITA Program: Legal Issues For Startups
February 25, 2013
Cambridge, MA

"The Capital for Clean-Tech Deals"
June 28, 2012
New York , NY

StartUp Legal Workshop "Unplugged"
February 29, 2012
Allston , MA

BioPharm America
September 7, 2011
Boston , MA

The 510(k) Program and FDA’s Initiatives
2011 Medical Device Series Presentation
June 15, 2011